CA3204788C - ANTIBODIES COMPRISING AN ANTIGEN BINDING SITE THAT BINDS PRECISELY TO TWO DIFFERENT ANTIGENIC DETERMINANTS, AND METHODS OF PRODUCTION - Google Patents

ANTIBODIES COMPRISING AN ANTIGEN BINDING SITE THAT BINDS PRECISELY TO TWO DIFFERENT ANTIGENIC DETERMINANTS, AND METHODS OF PRODUCTION

Info

Publication number
CA3204788C
CA3204788C CA3204788A CA3204788A CA3204788C CA 3204788 C CA3204788 C CA 3204788C CA 3204788 A CA3204788 A CA 3204788A CA 3204788 A CA3204788 A CA 3204788A CA 3204788 C CA3204788 C CA 3204788C
Authority
CA
Canada
Prior art keywords
amino acid
acid sequence
seq
antibody
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3204788A
Other languages
English (en)
French (fr)
Other versions
CA3204788A1 (en
Inventor
Germaine Fuh
Chingwei V. Lee
Patrick Koenig
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Priority to CA3204788A priority Critical patent/CA3204788C/en
Publication of CA3204788A1 publication Critical patent/CA3204788A1/en
Application granted granted Critical
Publication of CA3204788C publication Critical patent/CA3204788C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3204788A 2013-12-20 2014-12-18 ANTIBODIES COMPRISING AN ANTIGEN BINDING SITE THAT BINDS PRECISELY TO TWO DIFFERENT ANTIGENIC DETERMINANTS, AND METHODS OF PRODUCTION Active CA3204788C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3204788A CA3204788C (en) 2013-12-20 2014-12-18 ANTIBODIES COMPRISING AN ANTIGEN BINDING SITE THAT BINDS PRECISELY TO TWO DIFFERENT ANTIGENIC DETERMINANTS, AND METHODS OF PRODUCTION

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201361919552P 2013-12-20 2013-12-20
US61/919,552 2013-12-20
US201461946547P 2014-02-28 2014-02-28
US61/946,547 2014-02-28
CA3204788A CA3204788C (en) 2013-12-20 2014-12-18 ANTIBODIES COMPRISING AN ANTIGEN BINDING SITE THAT BINDS PRECISELY TO TWO DIFFERENT ANTIGENIC DETERMINANTS, AND METHODS OF PRODUCTION
CA2931113A CA2931113C (en) 2013-12-20 2014-12-18 Antibodies comprising an antigen-binding site that specifically binds to two different epitopes and methods of making them

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2931113A Division CA2931113C (en) 2013-12-20 2014-12-18 Antibodies comprising an antigen-binding site that specifically binds to two different epitopes and methods of making them

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3276932 Division 2014-12-18

Publications (2)

Publication Number Publication Date
CA3204788A1 CA3204788A1 (en) 2015-06-25
CA3204788C true CA3204788C (en) 2025-11-18

Family

ID=52293284

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2931113A Active CA2931113C (en) 2013-12-20 2014-12-18 Antibodies comprising an antigen-binding site that specifically binds to two different epitopes and methods of making them
CA3204788A Active CA3204788C (en) 2013-12-20 2014-12-18 ANTIBODIES COMPRISING AN ANTIGEN BINDING SITE THAT BINDS PRECISELY TO TWO DIFFERENT ANTIGENIC DETERMINANTS, AND METHODS OF PRODUCTION

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA2931113A Active CA2931113C (en) 2013-12-20 2014-12-18 Antibodies comprising an antigen-binding site that specifically binds to two different epitopes and methods of making them

Country Status (10)

Country Link
US (5) US10683348B2 (enExample)
EP (1) EP3083682B1 (enExample)
JP (4) JP7325166B2 (enExample)
KR (3) KR20230155605A (enExample)
CN (2) CN105849124B (enExample)
BR (1) BR112016011027A2 (enExample)
CA (2) CA2931113C (enExample)
MX (2) MX380937B (enExample)
RU (1) RU2732032C2 (enExample)
WO (1) WO2015095539A1 (enExample)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3448391T3 (pl) 2016-04-27 2024-09-16 AbbVie Manufacturing Management Unlimited Company Sposoby leczenia chorób, w których jest szkodliwa aktywność il-13, przy zastosowaniu przeciwciała anty-il-13
TW201829463A (zh) 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 抗hla-g抗體及其用途
IL268554B2 (en) 2017-02-08 2025-03-01 Dragonfly Therapeutics Inc Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
CA3235295C (en) 2017-02-20 2024-11-19 Dragonfly Therapeutics, Inc. Proteins binding her2, nkg2d and cd16
CN110382696B (zh) * 2017-03-07 2024-04-19 豪夫迈·罗氏有限公司 发现替代性抗原特异性抗体变体的方法
ES2955852T3 (es) 2017-04-03 2023-12-07 Hoffmann La Roche Anticuerpos de unión a STEAP-1
BR112019018779A2 (pt) 2017-04-05 2020-05-05 Hoffmann La Roche anticorpos isolados, ácido nucleico isolado, célula hospedeira, método para tratar um indivíduo tendo câncer e para produzir um anticorpo, formulação farmacêutica e uso do anticorpo
MY201928A (en) 2017-09-29 2024-03-24 Shanghai hengrui pharmaceutical co ltd Il-5 antibody, antigen binding fragment thereof, and medical application therefor
MA51302A (fr) 2017-12-21 2021-03-31 Hoffmann La Roche Anticorps se liant à hla-a2/wt1
EP3746470A1 (en) 2018-01-31 2020-12-09 F. Hoffmann-La Roche AG Stabilized immunoglobulin domains
US20200354457A1 (en) 2018-01-31 2020-11-12 Hoffmann-La Roche Inc. Bispecific antibodies comprising an antigen-binding site binding to lag3
US12384847B2 (en) 2018-02-08 2025-08-12 Dragonfly Therapeutics, Inc. Cancer therapy involving an anti-PD1 antibody and a multi-specific binding protein that binds NKG2D, CD16, and a tumor-associated antigen
US11884733B2 (en) 2018-02-08 2024-01-30 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the NKG2D receptor
TWI829667B (zh) 2018-02-09 2024-01-21 瑞士商赫孚孟拉羅股份公司 結合gprc5d之抗體
US12215157B2 (en) 2018-02-20 2025-02-04 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind CD33, NKG2D, and CD16, and methods of use
KR20200135510A (ko) 2018-03-29 2020-12-02 제넨테크, 인크. 포유류 세포들에서 젖분비자극 활성의 조절
AR114789A1 (es) 2018-04-18 2020-10-14 Hoffmann La Roche Anticuerpos anti-hla-g y uso de los mismos
AR115052A1 (es) 2018-04-18 2020-11-25 Hoffmann La Roche Anticuerpos multiespecíficos y utilización de los mismos
MA53284A (fr) 2018-08-08 2022-01-26 Dragonfly Therapeutics Inc Protéines de liaison à nkg2d, à cd16 et à un antigène associé à une tumeur
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
EP3833392A4 (en) 2018-08-08 2022-05-18 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
MX2021007307A (es) 2018-12-21 2021-07-07 Hoffmann La Roche Anticuerpos que se unen a cd3.
JP7677892B2 (ja) 2018-12-28 2025-05-15 エフ． ホフマン－ラ ロシュ アーゲー 免疫応答が増幅された患者における治療的使用のためのペプチド－ｍｈｃ－ｉ－抗体融合タンパク質
US12465640B2 (en) 2019-02-25 2025-11-11 The University Of Chicago Methods and compositions for treating inflammatory and autoimmune conditions with ECM-affinity peptides linked to anti-inflammatory agents
CA3134401A1 (en) 2019-03-29 2020-10-08 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutical composition containing antibody against il-5 and use thereof
EP3947469A4 (en) 2019-04-02 2022-12-14 National Research Council of Canada PH-DEPENDENT ANTIGEN-BINDING ANTIBODY VARIANTS FOR SELECTIVE TARGETING OF SOLID TUMORS
BR112021021972A2 (pt) 2019-05-03 2021-12-21 Hoffmann La Roche Métodos de redução de uma taxa de atividade de hidrólise enzimática, de redução do nível de uma ou mais enzimas hidrolíticas e de redução da degradação de um polissorbato, composições farmacêuticas e composições de porção de anticorpo formulada
ES3027485T3 (en) 2019-06-26 2025-06-16 Hoffmann La Roche Mammalian cell lines with sirt-1 gene knockout
AR119393A1 (es) 2019-07-15 2021-12-15 Hoffmann La Roche Anticuerpos que se unen a nkg2d
BR112022001460A2 (pt) 2019-07-31 2022-03-22 Hoffmann La Roche Moléculas de ligação ao antígeno biespecíficas, um ou mais polinucleotídeos isolados, célula hospedeira, método para produzir uma molécula de ligação ao antígeno biespecífica e para tratar uma doença em um indivíduo, composição farmacêutica, uso da molécula de ligação ao antígeno biespecífica e invenção
CN114174338A (zh) 2019-07-31 2022-03-11 豪夫迈·罗氏有限公司 与gprc5d结合的抗体
AR119997A1 (es) 2019-09-18 2022-01-26 Genentech Inc Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5 / klk7 y métodos de uso
BR112022008172A2 (pt) 2019-11-15 2022-07-12 Hoffmann La Roche Composição aquosa estável, método para obter uma composição e forma de dosagem farmacêutica
EP4076666A1 (en) 2019-12-18 2022-10-26 F. Hoffmann-La Roche AG Antibodies binding to hla-a2/mage-a4
WO2021122733A1 (en) 2019-12-18 2021-06-24 F. Hoffmann-La Roche Ag Bispecific anti-ccl2 antibodies
MX2022007746A (es) 2019-12-23 2022-10-07 Genentech Inc Anticuerpos especificos de apolipoproteina l1 y metodos de uso.
EP4090666A1 (en) 2020-01-15 2022-11-23 F. Hoffmann-La Roche AG Methods to decrease impurities from recombinant protein manufacturing processes
CA3169908A1 (en) 2020-03-26 2021-09-30 Genentech, Inc. Modified mammalian cells having reduced host cell proteins
TW202208428A (zh) 2020-05-06 2022-03-01 美商蜻蜓醫療公司 結合ｎｋｇ２ｄ、ｃｄ１６及ｃｌｅｃ１２ａ之蛋白質
EP4149421A1 (en) 2020-05-15 2023-03-22 F. Hoffmann-La Roche AG Prevention of visible particle formation in parenteral protein solutions
EP4153130A1 (en) 2020-05-19 2023-03-29 F. Hoffmann-La Roche AG The use of chelators for the prevention of visible particle formation in parenteral protein solutions
IL298302A (en) 2020-06-08 2023-01-01 Hoffmann La Roche Anti-hbv antibodies and methods of use
PE20231080A1 (es) 2020-06-19 2023-07-17 Hoffmann La Roche Anticuerpos que se unen a cd3 y cd19
WO2021255146A1 (en) 2020-06-19 2021-12-23 F. Hoffmann-La Roche Ag Antibodies binding to cd3 and cea
WO2021255142A1 (en) 2020-06-19 2021-12-23 F. Hoffmann-La Roche Ag Antibodies binding to cd3
WO2021255143A1 (en) 2020-06-19 2021-12-23 F. Hoffmann-La Roche Ag Antibodies binding to cd3 and folr1
IL299161A (en) 2020-06-24 2023-02-01 Genentech Inc Cell lines resistant to apoptosis
EP4178529A1 (en) 2020-07-07 2023-05-17 F. Hoffmann-La Roche AG Alternative surfactants as stabilizers for therapeutic protein formulations
MX2023000617A (es) 2020-07-17 2023-02-13 Genentech Inc Anticuerpos anti-notch2 y metodos de uso.
TW202227625A (zh) 2020-08-28 2022-07-16 美商建南德克公司 宿主細胞蛋白質之ＣＲＩＳＰＲ／Ｃａｓ９多重剔除
CA3195257A1 (en) 2020-09-24 2022-03-31 F. Hoffmann-La Roche Ag Mammalian cell lines with gene knockout
WO2022086957A1 (en) 2020-10-20 2022-04-28 Genentech, Inc. Peg-conjugated anti-mertk antibodies and methods of use
EP4244248A1 (en) 2020-11-16 2023-09-20 F. Hoffmann-La Roche AG Fab high mannose glycoforms
IL303656A (en) 2020-12-17 2023-08-01 Hoffmann La Roche Anti-hla-g antibodies and use thereof
EP4267734A1 (en) 2020-12-22 2023-11-01 F. Hoffmann-La Roche AG Oligonucleotides targeting xbp1
EP4281474A4 (en) * 2021-01-21 2025-03-05 Biolojic Design Ltd. Dual binding antibodies, methods of producing dual binding antibodies, and uses thereof
JP2024509695A (ja) 2021-02-03 2024-03-05 ジェネンテック， インコーポレイテッド 多重特異性結合タンパク質分解プラットフォームおよび使用方法
EP4301774A4 (en) 2021-03-03 2025-08-13 Dragonfly Therapeutics Inc METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
WO2022192647A1 (en) 2021-03-12 2022-09-15 Genentech, Inc. Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
WO2022214565A1 (en) 2021-04-09 2022-10-13 F. Hoffmann-La Roche Ag Process for selecting cell clones expressing a heterologous polypeptide
WO2022225880A1 (en) 2021-04-19 2022-10-27 Genentech, Inc. Modified mammalian cells
WO2022246259A1 (en) 2021-05-21 2022-11-24 Genentech, Inc. Modified cells for the production of a recombinant product of interest
CA3221735A1 (en) 2021-06-18 2022-12-22 F. Hoffmann-La Roche Ag Bispecific anti-ccl2 antibodies
KR20240032930A (ko) 2021-07-13 2024-03-12 제넨테크, 인크. 사이토카인 방출 증후군을 예측하기 위한 다변량 모델
KR20240036570A (ko) 2021-07-22 2024-03-20 에프. 호프만-라 로슈 아게 이종이량체 Fc 도메인 항체
US20250215103A1 (en) 2021-08-03 2025-07-03 Hoffmann-La Roche Inc. Bispecific antibodies and methods of use
AR127887A1 (es) 2021-12-10 2024-03-06 Hoffmann La Roche Anticuerpos que se unen a cd3 y plap
WO2023117325A1 (en) 2021-12-21 2023-06-29 F. Hoffmann-La Roche Ag Method for the determination of hydrolytic activity
TW202340251A (zh) 2022-01-19 2023-10-16 美商建南德克公司 抗ｎｏｔｃｈ２抗體及結合物及其使用方法
IL315262A (en) * 2022-03-03 2024-10-01 Pfizer Multiple specific antibodies related to IL-4, IL-13 and/or TSLP and their uses
WO2023202967A1 (en) 2022-04-19 2023-10-26 F. Hoffmann-La Roche Ag Improved production cells
CA3239182A1 (en) * 2022-05-23 2023-11-30 Zhipeng SU Stable antibody preparation
KR20250018382A (ko) 2022-05-30 2025-02-05 한올바이오파마주식회사 안정성이 향상된 항-FcRn 항체 또는 이의 항원 결합 단편
WO2023232961A1 (en) 2022-06-03 2023-12-07 F. Hoffmann-La Roche Ag Improved production cells
CR20250009A (es) 2022-06-17 2025-05-07 Apogee Biologics Inc Anticuerpos que se unen a interleuquina 13 y métodos de uso
CR20250056A (es) 2022-07-22 2025-03-19 Genentech Inc Moléculas de unión al antígeno anti-steap1 y sus usos.
TW202423970A (zh) 2022-10-10 2024-06-16 瑞士商赫孚孟拉羅股份公司 Ｇｐｒｃ５ｄ ｔｃｂ及ｃｄ３８抗體之組合療法
TW202430211A (zh) 2022-10-10 2024-08-01 瑞士商赫孚孟拉羅股份公司 Ｇｐｒｃ５ｄ ｔｃｂ及ｉｍｉｄ之組合療法
TW202423969A (zh) 2022-10-10 2024-06-16 瑞士商赫孚孟拉羅股份公司 Ｇｐｒｃ５ｄ ｔｃｂ及蛋白酶體抑制劑之組合療法
WO2024079069A1 (en) 2022-10-12 2024-04-18 F. Hoffmann-La Roche Ag Method for classifying cells
JP2025538565A (ja) 2022-11-23 2025-11-28 エフ． ホフマン－ラ ロシュ アーゲー 組換えタンパク質発現を増加させるための方法
CN119998314A (zh) 2022-12-08 2025-05-13 长春百克生物科技股份公司 特异性结合rsv的抗体
JP2025538819A (ja) 2022-12-12 2025-11-28 ジェネンテック， インコーポレイテッド ポリペプチドシアル酸含有量の最適化
CN120569410A (zh) 2023-01-25 2025-08-29 豪夫迈·罗氏有限公司 与csf1r和cd3结合的抗体
CN120826234A (zh) 2023-03-06 2025-10-21 豪夫迈·罗氏有限公司 抗EGFRvIII/抗CD3抗体与肿瘤靶向性4-1BB激动剂的组合疗法
CN120858109A (zh) 2023-03-10 2025-10-28 基因泰克公司 与蛋白酶的融合物及其用途
CN120936626A (zh) 2023-03-31 2025-11-11 基因泰克公司 抗αvβ8整合素抗体及使用方法
AU2024269754A1 (en) 2023-05-08 2025-10-23 F. Hoffmann-La Roche Ag Targeted interferon alpha fusion proteins and methods of use
TW202502809A (zh) 2023-06-22 2025-01-16 美商建南德克公司 抗體及其用途
WO2025021838A1 (en) 2023-07-26 2025-01-30 F. Hoffmann-La Roche Ag Antibodies binding to cd3
WO2025032071A1 (en) 2023-08-09 2025-02-13 F. Hoffmann-La Roche Ag Mono and multispecific anti-trem2 antibodies, methods and uses thereof
WO2025032069A1 (en) 2023-08-09 2025-02-13 F. Hoffmann-La Roche Ag Mono and multispecific anti-trem2 antibodies, methods and uses thereof
WO2025040567A1 (en) 2023-08-18 2025-02-27 F. Hoffmann-La Roche Ag Protease activatable fc domain binding molecules
JP2025036273A (ja) * 2023-08-30 2025-03-14 ファイザー・インク 多重特異性抗体およびその使用
AR133909A1 (es) 2023-09-25 2025-11-12 Hoffmann La Roche ANTICUERPO QUE SE UNE A C3bBb
WO2025125386A1 (en) 2023-12-14 2025-06-19 F. Hoffmann-La Roche Ag Antibodies that bind to folr1 and methods of use
WO2025132503A1 (en) 2023-12-20 2025-06-26 F. Hoffmann-La Roche Ag Antibodies binding to ceacam5
WO2025137086A1 (en) 2023-12-20 2025-06-26 Genentech, Inc. Reducing alpha-gal
WO2025133042A2 (en) 2023-12-22 2025-06-26 F. Hoffmann-La Roche Ag Activatable fusion proteins and methods of use
WO2025181189A1 (en) 2024-03-01 2025-09-04 F. Hoffmann-La Roche Ag Antibodies binding to cd3
WO2025215060A1 (en) 2024-04-11 2025-10-16 F. Hoffmann-La Roche Ag Antibodies that specifically bind modified oligonucleotides

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
EP0617706B1 (en) 1991-11-25 2001-10-17 Enzon, Inc. Multivalent antigen-binding proteins
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6165463A (en) 1997-10-16 2000-12-26 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
JP4955185B2 (ja) * 2000-06-29 2012-06-20 アボット・ラボラトリーズ 二重特異性抗体ならびに作製方法および使用方法
WO2003002609A2 (en) * 2001-06-28 2003-01-09 Domantis Limited Dual-specific ligand and its use
AU2003244817B2 (en) * 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs
ZA200702427B (en) * 2004-09-17 2008-12-31 Domantis Ltd Compositions monovalent for CD40L binding and methods of use
US10118970B2 (en) * 2006-08-30 2018-11-06 Genentech, Inc. Multispecific antibodies
JP2010527325A (ja) * 2007-04-02 2010-08-12 ジェネンテック， インコーポレイテッド Ｂ細胞アンタゴニストに応答する関節リウマチを予測するバイオマーカー
EP2050764A1 (en) * 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
MA33198B1 (fr) * 2009-03-20 2012-04-02 Genentech Inc Anticorps anti-her di-spécifiques
JP5901517B2 (ja) 2009-05-28 2016-04-13 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ 抗原結合性タンパク質
SI2726510T1 (sl) 2011-05-27 2023-06-30 F. Hoffmann - La Roche Ag Dvojno ciljanje
MX2015013901A (es) * 2013-04-05 2015-12-11 Genentech Inc Anticuerpos anti-il-4 y anticuerpos biespecificos y sus usos.

Also Published As

Publication number Publication date
JP2023179409A (ja) 2023-12-19
CN114702594B (zh) 2025-05-09
CA2931113A1 (en) 2015-06-25
BR112016011027A2 (pt) 2017-12-05
EP3083682C0 (en) 2024-04-17
MX380937B (es) 2025-03-12
CN105849124A (zh) 2016-08-10
JP7504664B2 (ja) 2024-06-24
RU2732032C2 (ru) 2020-09-10
JP2020162609A (ja) 2020-10-08
WO2015095539A1 (en) 2015-06-25
CA2931113C (en) 2023-07-11
US20250109195A1 (en) 2025-04-03
JP7325166B2 (ja) 2023-08-14
US20160257744A1 (en) 2016-09-08
KR102597804B1 (ko) 2023-11-07
MX2021003549A (es) 2021-05-27
CN105849124B (zh) 2022-04-12
US20200255512A1 (en) 2020-08-13
US10683348B2 (en) 2020-06-16
KR20250154523A (ko) 2025-10-28
KR20230155605A (ko) 2023-11-10
US20250346661A1 (en) 2025-11-13
US20240279327A1 (en) 2024-08-22
KR20160099086A (ko) 2016-08-19
EP3083682B1 (en) 2024-04-17
US12006360B2 (en) 2024-06-11
EP3083682A1 (en) 2016-10-26
MX2016006529A (es) 2016-08-03
CN114702594A (zh) 2022-07-05
RU2016129247A (ru) 2018-01-25
RU2020129339A (ru) 2020-10-02
CA3204788A1 (en) 2015-06-25
JP2017501711A (ja) 2017-01-19
JP2025179073A (ja) 2025-12-09

Similar Documents

Publication Publication Date Title
US20250109195A1 (en) Dual specific antibodies
US20240043547A1 (en) Antibody variable domains that bind il-31
JP2012517818A (ja) 改善された抗ｔｎｆｒ１ポリペプチド、抗体可変ドメインおよびアンタゴニスト
CN108473568A (zh) 对TNF-α、IL-17A和IL-17F具有特异性的多特异性抗体分子
CN106565840B (zh) 抗乙肝表面抗原的抗体及其用途
CN110494445A (zh) 抗α-SYN抗体及其用途
CN110678196A (zh) 抗hekr-k包膜抗体及其用途
US20240228626A1 (en) Anti-nkg2d antibodies and uses thereof
RU2852376C2 (ru) Антитела с двойной специфичностью
HK40077418A (zh) 双重特异性抗体
US20250002596A1 (en) Neutralizing anti-cd95l monoclonal antibodies
HK1227892A1 (en) Dual specific antibodies
HK1227892B (en) Dual specific antibodies
KR20240150754A (ko) 메탈로프로테아제에 의한 cd95l의 절단을 방지하기 위한 항체
NZ796415A (en) Anti-herv-k envelope antibody and uses thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230626

EEER Examination request

Effective date: 20230626

EEER Examination request

Effective date: 20230626